$16 billion on the table
Have you noticed all the marketing on instagram and tiktok on peptides, GLP1, and weight loss drug analogs? Did you ever wonder why it became such a huge thing early 2026? Guess what else happened in early 2026… Wegovy, a blockbuster chronic weight management drug developed by Novo Nordisk lost it’s exclusivity. So a surge of generics were legally allowed to come in to market and sell similar drugs. This happens more often than you think, and as many pharmaceutical companies face patent cliffs over the next 5 years (multi-year stretch where blockbuster drugs lose their exclusivity protection and face cheap generic competition virtually overnight), I thought of an interesting merger and acquisition play that Pfizer can potentially execute to strategically continue growing it’s pipeline.
In the world of mergers and acquisitions, the best deals share a common trait: they solve a real problem for the buyer while creating genuine value for the seller's shareholders. The proposed acquisition of Exelixis Pharmaceuticals (NASDAQ: EXEL) by Pfizer (NYSE: PFE) checks both boxes with unusual precision. At a recommended initial offer of $65.00 per share, representing a 29.3% premium to Exelixis's current trading price, this deal is not just strategically sensible, it could possible be one of the most well-timed and well-priced acquisitions Pfizer could make right now - holding a deal value of a whopping $16.3 billion.
In 2026 alone, Pfizer has guided to approximately $1.5 billion in revenue headwinds from loss-of-exclusivity events. But 2027 is where the real pain arrives. Ibrance, Pfizer's flagship breast cancer drug that generates billions in annual revenue, simultaneously faces patent expiry and Medicare price negotiation under the Inflation Reduction Act in the same calendar year. Wall Street analysts have modeled Pfizer's adjusted earnings per share bottoming out at approximately $2.49 in 2028 before a recovery is projected to begin in 2029. Pfizer's CEO has publicly acknowledged this dynamic, projecting "high single-digit revenue CAGR" starting in 2029. The problem is the gap between now and then. That three-year trough needs to be bridged, and organic drug development alone (which can take five to 10 years from discovery to approval) can’t fill it in time. The fastest path to replacing lost revenue is a targeted, strategically aligned acquisition.
Exelixis is not a speculative bet. It is a profitable, cash-generating commercial oncology company with a dominant product, a filed next-generation drug, and a pipeline that happens to map directly onto Pfizer's stated strategic priorities. Cabometyx, the brand name for cabozantinib, is the number-one prescribed tyrosine kinase inhibitor (TKI) in U.S. renal cell carcinoma (kidney cancer) with approximately 44% market share. It generated $2.89 billion in global net product revenue in 2025, growing 17% in the United States. The FDA approved a new indication for neuroendocrine tumors in March 2025, immediately capturing approximately 35% of new patient share in that segment. And critically, the intellectual property protecting Cabometyx is locked up and can’t be touched by generic competition through 2030 and 2031 at the earliest.
One single asset might turn to two assets soon… First Carbometix, then there is zanzalintinib, Exelixis's next-generation TKI. In October 2025, results from the Phase 3 STELLAR-303 trial showed a statistically significant improvement in overall survival versus the standard of care in previously treated metastatic colorectal cancer, one of the most common and lethal cancers in the United States with approximately 154,000 new cases diagnosed annually. Exelixis filed an NDA with the FDA in 2025, with an action date expected in late 2026. If approved, zanzalintinib opens an entirely new market for the company
This acquisition creates long-term strategic value that a revenue replacement deal rarely achieves. Pfizer's oncology strategy, as articulated at its 2024 Oncology Innovation Day, centers on three drug modalities: small molecules, antibody-drug conjugates, and bispecific antibodies. Pfizer acquired Seagen in 2023 for $43 billion specifically to build its ADC capability. Exelixis's pipeline would extend that capability with an in-house biotherapeutics network for custom ADC generation that Pfizer currently lacks. The deal also diversifies Pfizer across tumor types, adding renal cell carcinoma, neuroendocrine tumors, and colorectal cancer to Pfizer's existing focus on breast cancer, hematology, thoracic, and GU cancers.
The best M&A deals are ones where both sides have a reason to say yes. Exelixis shareholders would receive a 29% premium to a stock that has already appreciated significantly and faces execution risk on zanzalintinib as a standalone company. Pfizer shareholders would receive immediate earnings support through their company's most difficult revenue period, a second pipeline franchise, and a platform that extends their oncology strategy for the next decade.
——
Walida Ali is a graduate student in Mergers & Acquisitions at Johns Hopkins University. This article is based on academic work completed as part of a graduate M&A course and does not constitute investment advice. All financial data is sourced from publicly available SEC filings, Federal Reserve releases, and analyst consensus databases. Pfizer has not announced any acquisition of Exelixis.
